The DEA Announces Proposed Rules for Permanent Telemedicine Flexibilities

Last week, the Drug Enforcement Administration (DEA) announced proposed rules for the prescribing of controlled medications via telemedicine beyond the end of the COVID-19 public health emergency. One rule addresses the expansion of induction of buprenorphine via telemedicine encounter while the other covers telemedicine prescribing of controlled substances when the practitioner and the patient have not had a prior in-person medical evaluation. While opioid use disorders occur at similar rates in both rural and urban areas, medication-assisted treatment (MAT) prescribers have been disproportionately located in urban areas. Comments are due by March 31, 2023.